Sivextro
NDC Package 72000-310-06
Package Information
Sivextro is a medication used to treat serious bacterial infections of the skin. Marketed by Nabriva Therapeutics Us, Inc., this product is identified by NDC 72000-310 and is authorized under FDA application NDA205435.
Identification & Billing
- RxCUI: 1540862 - tedizolid phosphate 200 MG Oral Tablet
- RxCUI: 1540868 - Sivextro 200 MG Oral Tablet
- RxCUI: 1540868 - tedizolid phosphate 200 MG Oral Tablet [Sivextro]
- RxCUI: 1540886 - tedizolid phosphate 200 MG Injection
- RxCUI: 1540890 - Sivextro 200 MG Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72000 - Nabriva Therapeutics Us, Inc.
- 72000-310 - Sivextro
- 72000-310-06 - 1 BLISTER PACK in 1 CARTON / 6 TABLET, FILM COATED in 1 BLISTER PACK
- 72000-310 - Sivextro
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72000-310). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72000-310-06 identifies a specific commercial package of 1 blister pack in 1 carton / 6 tablet, film coated in 1 blister pack of Sivextro, labeled by Nabriva Therapeutics Us, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Nabriva Therapeutics Us, Inc. on June 20, 2014. The current certification is valid through December 31, 2025.
What are the primary indications for this medication?
This medication is used to treat serious bacterial infections of the skin. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
How is this Nabriva Therapeutics Us, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72000031006. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.